BioMarin Pays $275M Upfront for Alesta to Challenge AstraZeneca in Rare Bone Disease — BigGo Finance
BioMarin Pharmaceutical Inc. (BMRN) has agreed to acquire Alesta Therapeutics for $275 million in upfront cash, securing an…
Browsing Tag